Weaning Algorithm for Mechanical VEntilation
Launched by ROYAL BROMPTON & HAREFIELD NHS FOUNDATION TRUST · Oct 4, 2018
Trial Information
Current as of May 08, 2025
Unknown status
Keywords
ClinConnect Summary
Patients admitted to the intensive care unit typically receive invasive mechanical ventilatory support when they are critically ill. Whilst mechanical ventilation is a life-saving intervention, it can also lead to deleterious consequences and cause lung damage (known as ventilator-associated lung injury) if not implemented carefully. Hence, reducing the duration of mechanical ventilation should reduce complications such as ventilator-associated lung injury, ventilator-acquired pneumonia, respiratory and skeletal muscle wasting, and patient discomfort, leading to decreasing mortality and eco...
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Patient remains on mechanical ventilation at 24 hours following intubation.
- • Age \> 18 years
- • Patient consent or, in the case that the patient is unable, advice from the next of kin or treating physician following understanding and acceptance of oral and written information describing the study.
- Exclusion criteria:
- • The absence of an arterial catheter for blood sampling at study start.
- • Mechanical ventilation initiated for more than 48 hours.
- • Medical history of home mechanical ventilation which may lead to prolonged stay in the ICU, including long term oxygen therapy and non-invasive ventilation not associated with sleep apnoea.
- • Patients mechanically ventilated in a ventilator mode, and by a ventilator not supported by the Beacon Caresystem on screening.
- • Respiratory failure likely requiring extracorporeal support.
- • Severe cardiogenic shock likely requiring extracorporeal support.
- • Severe isolated right heart failure.
- • Head trauma or other conditions where intra-cranial pressure may be elevated and tight regulation of arterial CO2 level is paramount.
- • Primary (non-overdose related) neurological patients (Glasgow coma score \<10, neurologic damage with limited prognosis, stroke hemiplegia).
- • End stage liver disease.
- • Repeated ICU admission within same hospital admission and/or likely to have prolonged ICU stay with mechanical ventilation (\>21 days)
- • Pregnancy.
About Royal Brompton & Harefield Nhs Foundation Trust
Royal Brompton & Harefield NHS Foundation Trust is a leading specialist healthcare provider in the United Kingdom, renowned for its expertise in cardiothoracic medicine and respiratory care. Committed to advancing clinical research and improving patient outcomes, the Trust conducts a diverse range of clinical trials aimed at exploring innovative treatments and therapies. With a multidisciplinary team of clinicians and researchers, the Foundation Trust fosters a collaborative environment that prioritizes patient safety and ethical standards, contributing significantly to the global body of medical knowledge and enhancing the quality of care for patients with complex health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Uxbridge, , United Kingdom
Patients applied
Trial Officials
Brijesh Patel, MBBS PhD
Principal Investigator
Royal Brompton & Harefield NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials